Compositions and methods for providing desired cannabinoid content in cannabis plants. More particularly, the invention relates to compositions and methods for using cannabinoid synthase paralogs as guidance for breeding cannabis plants with a desired cannabinoid content, including but not limited to cultivars, varieties, lines and methods of breeding the same for commercial use.

An apparatus with a projection defining first and second openings and a channel between the openings. An interior surface adjacent the channel tapers inwardly from the first opening to the second opening, and a shearing edge is positioned adjacent the second opening. A method of using the apparatus to separate protuberances of a plant from an elongate portion of the plant by pulling the elongate portion through the channel. Another apparatus with first and second counter-rotating rollers. Each roller having alternating projecting portions and valleys and oriented so that projecting portions of one roller are aligned with valleys of the other roller as the rollers rotate. A method of using the rollers to deform an elongate portion of a plant between the projecting portions of one roller and the valleys of the other roller.

Synthetic cannabinoid compounds for treatment of epilepsy, substance addiction, and Alzheimer's disease by administering to an individual in need thereof a pharmaceutical composition including a compound having the structure: ##STR00001##
or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable vehicle therefor.

The unique annual herbaceous Cannabis plant variety ‘VB252X’ is provided. The variety can be distinguished by its outstanding features of increased vigor and large size.

The unique annual herbaceous Cannabis plant variety ‘VB252X’ is provided. The variety can be distinguished by its outstanding features of increased vigor and large size.

A method of producing cannabinoids for use in medical treatments by growing cultured Cannabis sativa plant cells through tissue culture, the method comprising the steps of: selecting Cannabis sativa leaf tissue for culture; and growing a tissue culture from the selected leaf tissue in a liquid based medium whilst controlling the light exposure of the tissue culture to control the cannabinoid content of the tissue culture. Control of the light exposure can enable the phytocannabinoid content of the grown tissue culture to be tailored to the use intended for the tissue culture. For example, the THC content of the tissue culture can be controlled to be maximised or minimised depending on the intended use. Use of tissue culture is beneficial as compared to prior art methods as it allows for genetic consistency and reduces the resources necessary to produce plant cells containing phytocannabinoids.

A method of producing cannabinoids for use in medical treatments by growing cultured Cannabis sativa plant cells through tissue culture, the method comprising the steps of: selecting Cannabis sativa leaf tissue for culture; and growing a tissue culture from the selected leaf tissue in a liquid based medium whilst controlling the light exposure of the tissue culture to control the cannabinoid content of the tissue culture. Control of the light exposure can enable the phytocannabinoid content of the grown tissue culture to be tailored to the use intended for the tissue culture. For example, the THC content of the tissue culture can be controlled to be maximised or minimised depending on the intended use. Use of tissue culture is beneficial as compared to prior art methods as it allows for genetic consistency and reduces the resources necessary to produce plant cells containing phytocannabinoids.

This disclosure relates to new plants and methods for increasing and decreasing synthesis of cannabinoids. The plants disclosed herein comprise unnatural ratios and concentrations of cannabinoids in plants of genus Cannabis. The methods disclosed herein comprise manipulating the biosynthetic pathway of cannabinoids to produce plants of genus Cannabis with unnatural ratios and concentrations of cannabinoids.

The unique annual herbaceous Cannabis plant variety ‘ESB-1’ is provided. The variety can be distinguished by its outstanding features of a THCV cannabinoid content ratio of about 1 part THC to 1 part THCV and purple leaf stem, when grown under certain growing conditions.

The unique annual herbaceous Cannabis plant variety ‘ESB-1’ is provided. The variety can be distinguished by its outstanding features of a THCV cannabinoid content ratio of about 1 part THC to 1 part THCV and purple leaf stem, when grown under certain growing conditions.